Daniel S. Lynch

Biography

Mr. Daniel S. Lynch, also known as Dan, M.B.A. serves as Executive Chairman at SpringWorks Therapeutics, LLC. Mr. Lynch has been Executive Chairman of Surface Oncology, Inc. since January 4, 2017. Mr. Lynch has been Executive Chairman of Blueprint Medicines Corporation since September 2012. Mr. Lynch has been the Executive Chairman of Egenesis Inc. since March 2017. Mr. Lynch has been the President and Chief Executive Officer at IVREA Pharmaceuticals, Inc. since February 1, 2007. He has been a Venture Partner at Third Rock Ventures, LLC since May 14, 2013. He supports the commercial and business development of existing portfolio companies and serves as a strategic advisor across the portfolio. He has been Executive Chairman of Nimbus Therapeutics, Inc. (alternate name, Nimbus Discovery, LLC) since November 1, 2012. Until March, 2012, he served as an Executive Chairman of the board for two companies Celgene Avilomics Research, Inc. and Stromedix, Inc. He was an Entrepreneur-in-Residence of Third Rock Ventures, LLC from joining in May 2011 to May 2013. Mr. Lynch served as the Chief Executive Officer of ImClone Systems LLC (alternate name, ImClone Systems Corporation) from March 9, 2004 to November 10, 2005 and served as its Senior Vice President and Chief Administrative Officer from April 29, 2003 to November 10, 2005, Acting Chief Executive Officer from April 29, 2003 to March 9, 2004, Senior Vice President of Finance from September 2001 to April 29, 2003, Vice President of Finance since joining in April 2001 and served as its Chief Financial Officer from April 2001 to 2003, where he led negotiations related to the major partnership between ImClone and Bristol-Myers Squibb Company and led through a significant turnaround, helping restore its reputation and secure FDA approval of its novel cancer treatment ERBITUX. Mr. Lynch served as Secretary of ImClone Systems Inc. from February 2002 to April 29, 2003. He served as the Chief Financial Officer of The Derby Cycle Corporation from May 1999 to February 28, 2001. He served for 15 years in various capacities at Bristol-Myers Squibb Company, including as its Vice President of Finance, U.S. Pharmaceutical, Worldwide Medicines Group from December 1998 to May 1999. He served as Vice President of Finance, Technical Operations, Worldwide Medicines Group at Bristol-Myers Squibb Company from April 1998 to November 1998. He served as Vice President of Finance, Intercontinental, Worldwide Medicines Group at Bristol-Myers Squibb Company from July 1997 to March 1998 and served as its Vice President of Finance for Worldwide Consumer Medicines Group from February 1995 to June 1997. He has been the Chairman since May 2011 and has been its Director since May 16, 2011. He serves as Chairman of Translate Bio, Inc. and has been its Director since 2012. He has been the Chairman at bluebird bio, Inc. since May 16, 2011 and its Independent Director since May 16, 2011. He served as the Chairman at BIND Therapeutics, Inc. (now DNIB Unwind, Inc.) since October 2012 and served as its Director since September 20, 2012. He served as the Chairman of the Board at Eleven Biotherapeutics, Inc. from December 2013 to December 16, 2016. He serves as a Director at Avila Therapeutics, Inc., RaNA Therapeutics, Inc. and BIND Biosciences, Inc. Mr. Lynch has been a Director of Ivrea Pharmaceuticals, Inc., since January 2007. He served as a Director of Ember Therapeutics, Inc. Mr. Lynch served as a Director of Edimer Pharmaceuticals Inc. until May 2, 2013. He served as a Director of Eleven Biotherapeutics, Inc. since December 2013. He served as Director of US Oncology, Inc. from August 16, 2006 to 2010. He served as a Director of US Oncology Holdings, Inc. from August 16, 2006 to 2010. He served as a Director of ImClone Systems LLC from March 9, 2004 to November 10, 2005. Mr. Lynch holds an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia and a Bachelor of Arts in Mathematics from Wesleyan University.

Research Interest

Bussiness Management